Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Top Cited Papers
- 8 August 2016
- journal article
- practice guidelines
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 143 (1), 3-15
- https://doi.org/10.1016/j.ygyno.2016.05.022
Abstract
No abstract availableKeywords
Funding Information
- NIH (P30 CA008748, K07 CA166210)
This publication has 52 references indexed in Scilit:
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialThe Lancet Oncology, 2013
- Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancerGynecologic Oncology, 2011
- Defining the limits of radical cytoreductive surgery for ovarian cancerGynecologic Oncology, 2011
- Thirty-Day Mortality After Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the ElderlyObstetrics & Gynecology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerThe New England Journal of Medicine, 2010
- Preoperative serum CA‐125 levels and risk of suboptimal cytoreduction in ovarian cancer: A meta‐analysisJournal of Surgical Oncology, 2009
- Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the NetherlandsGynecologic Oncology, 2009
- Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009Gynecologic Oncology, 2009
- A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted modelGynecologic Oncology, 2007
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerThe New England Journal of Medicine, 1996